It's designed to take the place of complicated, multiple drug regimens that many people with HIV need to follow. And it's ...

Merck (MRK) announced on Wednesday that its single-tablet antiviral regimen, doravirine and islatravir for adults with HIV, was found to be non-inferior to Gilead’s (GILD) once-daily HIV pill Biktarvy ...

It could mark the "first advance to benefit people" who have been living with HIV for decades but are forced to treat it with complex, multi-pill regimens: a once a day pill that works just as well, ...

A public health emergency is about to emerge because of federal ADAP (AIDS Drug Assistance Program) funding cuts. Long since retired, but a public health educator to the end, I’d like to remind ...

The quest for a single-pill once-a-day treatment for HIV became a reality when the FDA approved Atripla on July 12. It combines the already approved drugs efavirenz (Sustiva), tenofovir (Viread), and ...

Brown researchers will look into how a drug originally developed to treat HIV may reduce age-related inflammation.

Thousands of low-income people living with HIV could be losing drug coverage as states impose limitations on HIV assistance programs amid constrained budgets — raising alarms over consistent access ...

Independent clinical validation strengthens ABL’s leadership in the fast‑growing HIV drug‑resistance testing market ABL ...

Starting Sunday, the state will cut its subsidies for the AIDS ​Drug Assistance Program (ADAP), and funds will only be available for people at or below 130% of the federal poverty level, a drop from ...